Chargement en cours...

Should minimal residual disease negativity be the end point of myeloma therapy?

Publisher's Note: This article has a companion Counterpoint by Sonneveld. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteur principal: Anderson, Kenneth C.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728451/
https://ncbi.nlm.nih.gov/pubmed/29296970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016000117
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!